Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city population

被引:0
|
作者
Dell'Aquila, Kevin [1 ]
Vadlamani, Abhinav [1 ]
Maldjian, Takouhie [1 ]
Fineberg, Susan [2 ]
Eligulashvili, Anna [1 ]
Chung, Julie [3 ]
Adam, Richard [1 ]
Hodges, Laura [1 ]
Hou, Wei [1 ]
Makower, Della [3 ]
Duong, Tim Q. [1 ,4 ]
机构
[1] Montefiore Hlth Syst & Albert Einstein Coll Med, Dept Radiol, 111 210th St, Bronx, NY 10467 USA
[2] Montefiore Hlth Syst & Albert Einstein Coll Med, Dept Pathol, Bronx, NY USA
[3] Montefiore Hlth Syst & Albert Einstein Coll Med, Dept Oncol, Bronx, NY USA
[4] Montefiore Hlth Syst & Albert Einstein Coll Med, Ctr Hlth Data Innovat, Bronx, NY USA
关键词
Molecular subtypes; Tumor subtypes; Socioeconomic status; Progression-free survival; Deep learning; Health disparity; BACKGROUND PARENCHYMAL ENHANCEMENT; CONVOLUTIONAL NEURAL-NETWORK; LYMPH-NODE METASTASIS; NEOADJUVANT CHEMOTHERAPY; SOCIOECONOMIC-STATUS; RACIAL DISPARITY; POOLED ANALYSIS; AMERICAN WOMEN; PRIMARY TUMOR; OUTCOMES;
D O I
10.1186/s13058-023-01762-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Generalizability of predictive models for pathological complete response (pCR) and overall survival (OS) in breast cancer patients requires diverse datasets. This study employed four machine learning models to predict pCR and OS up to 7.5 years using data from a diverse and underserved inner-city population. Methods Demographics, staging, tumor subtypes, income, insurance status, and data from radiology reports were obtained from 475 breast cancer patients on neoadjuvant chemotherapy in an inner-city health system (01/01/2012 to 12/31/2021). Logistic regression, Neural Network, Random Forest, and Gradient Boosted Regression models were used to predict outcomes (pCR and OS) with fivefold cross validation. Results pCR was not associated with age, race, ethnicity, tumor staging, Nottingham grade, income, and insurance status (p > 0.05). ER-/HER2+ showed the highest pCR rate, followed by triple negative, ER+/HER2+, and ER+/HER2- (all p < 0.05), tumor size (p < 0.003) and background parenchymal enhancement (BPE) (p < 0.01). Machine learning models ranked ER+/HER2-, ER-/HER2+, tumor size, and BPE as top predictors of pCR (AUC = 0.74-0.76). OS was associated with race, pCR status, tumor subtype, and insurance status (p < 0.05), but not ethnicity and incomes (p > 0.05). Machine learning models ranked tumor stage, pCR, nodal stage, and triple-negative subtype as top predictors of OS (AUC = 0.83-0.85). When grouping race and ethnicity by tumor subtypes, neither OS nor pCR were different due to race and ethnicity for each tumor subtype (p > 0.05). Conclusion Tumor subtypes and imaging characteristics were top predictors of pCR in our inner-city population. Insurance status, race, tumor subtypes and pCR were associated with OS. Machine learning models accurately predicted pCR and OS.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] MRI in diagnosis of pathological complete response in breast cancer patients after neoadjuvant chemotherapy
    Li, Yan-Ling
    Zhang, Xiao-Peng
    Li, Jie
    Cao, Kun
    Cui, Yong
    Li, Xiao-Ting
    Sun, Ying-Shi
    EUROPEAN JOURNAL OF RADIOLOGY, 2015, 84 (02) : 242 - 249
  • [42] Machine learning prediction of pathological complete response to neoadjuvant chemotherapy with peritumoral breast tumor ultrasound radiomics: compare with intratumoral radiomics and clinicopathologic predictors
    Jiejie Yao
    Wei Zhou
    Xiaohong Jia
    Ying Zhu
    Xiaosong Chen
    Weiwei Zhan
    Jianqiao Zhou
    Breast Cancer Research and Treatment, 2025, 212 (2) : 325 - 336
  • [43] The association between body mass index and pathological complete response in neoadjuvant-treated breast cancer patients
    Skarping, Ida
    Blaabjerg Pedersen, Stine
    Fornvik, Daniel
    Zackrisson, Sophia
    Borgquist, Signe
    ACTA ONCOLOGICA, 2022, 61 (06) : 731 - 737
  • [44] Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy
    Woriax, Hannah E.
    Thomas, Samantha M.
    Plichta, Jennifer K.
    Rosenberger, Laura H.
    Botty van den Bruele, Astrid
    Chiba, Akiko
    Hwang, E. Shelley
    Dinome, Maggie L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14) : 1635 - 1645
  • [45] Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
    He, Jin
    Blair, Alex B.
    Groot, Vincent P.
    Javed, Ammar A.
    Burkhart, Richard A.
    Gemenetzis, Georgios
    Hruban, Ralph H.
    Waters, Kevin M.
    Poling, Justin
    Zheng, Lei
    Laheru, Daniel
    Herman, Joseph M.
    Makary, Martin A.
    Weiss, Matthew J.
    Cameron, John L.
    Wolfgang, Christopher L.
    ANNALS OF SURGERY, 2018, 268 (01) : 1 - 8
  • [46] Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Wunderle, Marius
    Haeberle, Lothar
    Hein, Alexander
    Jud, Sebastian M.
    Lux, Michael P.
    Hack, Carolin C.
    Emons, Julius
    Heindl, Felix
    Nabieva, Naiba
    Loehberg, Christian R.
    Schulz-Wendtland, Rudiger
    Hartmann, Arndt
    Beckmann, Matthias W.
    Fasching, Peter A.
    Gass, Paul
    BREAST CARE, 2021, 16 (03) : 254 - 262
  • [47] Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait
    Krishnan, Yamini
    Al Awadi, Shafika
    Sreedharan, P. S.
    Nair, Susovana Sujith
    Thuruthel, Sanjay
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (01) : E30 - E37
  • [48] Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study
    Zhu, Wenjie
    Xu, Binghe
    PLOS ONE, 2015, 10 (08):
  • [49] Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy
    Mathieu, M. C.
    Mazouni, C.
    Kesty, N. C.
    Zhang, Y.
    Scott, V.
    Passeron, J.
    Arnedos, M.
    Schnabel, C. A.
    Delaloge, S.
    Erlander, M. G.
    Andre, F.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 2046 - 2052
  • [50] Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
    Freitas, Ana Julia Aguiar de
    Causin, Rhafaela Lima
    Varuzza, Muriele Bertagna
    Hidalgo Filho, Cassio Murilo Trovo
    Silva, Vinicius Duval da
    Souza, Cristiano de Padua
    Marques, Marcia Maria Chiquitelli
    CANCERS, 2021, 13 (21)